
Radiopharm Receives Approval To Advance RAD-202 HER2 Trial Dosing
Radiopharm Therapeutics (ASX: RAD, NASDAQ: RADX) has received approval from the Data Safety and Mon…
COLITCO LLP accepts no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. COLITCO LLP or an associate may receive a commission for funds raised.